Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors – healthradar.net

Eli Lilly’s obesity pill remains a viable rival to Novo’s oral Wegovy despite data that underwhelmed investors

data Eli investors Lillys Novos Obesity Oral Pill Remains rival underwhelmed viable Wegovy

Previous ArticleRansomware attack on DaVita exposes data from 2.7M

Next Article Twin Health Secures $53M Financing Following Cleveland Clinic Trial Results

Healthradar

Leave A Reply